Clinical

medicine

Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina Collaborate on Scalable Clinical Whole-Genome Sequencing Initiative

NEW YORK, Dec. 3, 2020 /PRNewswire/ — Seeking to advance the scope of precision medicine, Weill Cornell Medicine, NewYork-Presbyterian Hospital, and Illumina, Inc. are entering into a collaboration to sequence the complete human genomes of thousands of consenting patients, in order to identify genetic alterations driving disease and potentially reveal previously unidentified therapies for treatment. The initiative, which also includes a collaboration between Weill Cornell Medicine, NewYork-Presbyterian Hospital, and the New York Genome Center (NYGC), aims to evaluate the diagnostic potential of whole-genome sequencing at scale, which allows the interrogation of the full genome sequence of a patient’s DNA. The goal is to better understand health problems and potential disease risks of individual patients, and to design more effective treatments, including the choice of specific drugs and their dosing.

Investigators will study the feasibility and viability of large-scale implementation of whole-genome sequencing within an academic medical center that is part of a major metropolitan health care system in the United States. Whole-genome sequencing has already been shown to improve patient care and disease prevention in specific clinical contexts, but few systems have deployed whole-genome sequencing across multiple care pathways. Weill Cornell Medicine, through its Caryl and Israel Englander Institute for Precision Medicine, and NewYork-Presbyterian/Weill Cornell Medical Center, which have applied this precision medicine approach to investigate cancer’s molecular underpinnings since 2015, will be among the first medical institutions to examine the feasibility of large-scale whole-genome sequencing across multiple diseases. In addition to revealing the role individual genes play in disease and therapeutic responses, the study could also yield promising new avenues for scientific inquiry.

Under the initiative, which originates from Weill Cornell Medicine’s Englander Institute for Precision Medicine, doctors at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center will offer qualifying patients the option to have their genomes sequenced as part of their diagnostic workups. NYGC will leverage its high-throughput whole-genome sequencing clinical sequencing expertise to investigate patients’ DNA, using Illumina’s patented Next-Generation Sequencing technology. NYGC was the first sequencing center in the country to gain regulatory approval for clinical whole-genome sequencing tests for genetic diseases and cancer from the New York State Department of Health Clinical Laboratory Evaluation Program. Board-certified molecular geneticists at NYGC will interpret and share the results with ordering physicians, who will then share them with their patients. The initiative will focus on the disease areas of oncology, cardiovascular, metabolic and neurodegenerative diseases. This first phase will inform the next steps to expand infrastructure to support more widespread testing in years to come.  

“We are committed to expanding whole-genome sequencing to cancer and other common diseases more broadly, so that the approach can eventually become a routine part of healthcare, an essential source of data for biomedical research and, importantly, enhance patient care,” said Dr. Olivier Elemento, director of the Englander Institute for Precision Medicine at Weill Cornell Medicine, who also leads joint precision medicine efforts at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “This project and the network of participating

Read More
medicine

Clinical trials are key to advancing medicine, including COVID-19 vaccine

MIAMI – Registered clinical trials reached record levels in the past year, increasing the demand for people willing to participate, and Miami resident Marilyn Strauss Diaz was eager to join a COVID-19 vaccine trial underway at the University of Miami Health System.

“We can’t depend on a lab rat. We have to have human trials for there to be a successful vaccine, so we have to have humans come forward and be a part of trials,” she said.

“Before COVID, we usually would have a couple of hundred clinical trials here going at the same time at the University of Miami that are focused on a lot of different diseases. With COVID, there was a slowdown and now we’re ramping up again and starting a lot of these studies,” said Dr. Olveen Carassquillo, who is part of the research team.

“COVID has the most urgency. That’s a public health crisis so a lot of research is focused on that, but we have a lot of landmark cancer studies going on with different treatment regimens and prevention studies. We also have a lot of cardiovascular disease, a lot of other studies focused on stroke, on preventing dementia,” Carassquillo added.

And South Florida’s diverse population makes it a major focus of research efforts, something Strauss Diaz is proud to be a part of.

“At the end, it will be beneficial to so many,” she said.

To learn more about clinical trials at the University of Miami Health System go to: https://umiamihealth.org/clinical-trials

Copyright 2020 by WPLG Local10.com – All rights reserved.

Source Article

Read More
medicine

Ionis announces AstraZeneca’s initiation of the Phase 2b clinical study of its antisense medicine targeting PCSK9 to lower LDL-cholesterol | News

CARLSBAD, Calif., Nov. 30, 2020 /PRNewswire/ — Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that the biopharmaceutical company AstraZeneca has initiated a Phase 2b clinical trial of ION449 (AZD8233), an investigational antisense medicine designed to reduce blood cholesterol levels in patients with dyslipidemia by targeting proprotein convertase subtilisin/kexin type 9 (PCSK9), an important regulator of low-density lipoprotein cholesterol (LDL-C). PCSK9 is an enzyme that controls the number of LDL receptors on the surface of cells. People with genetic variations that reduce PCSK9 function have lower LDL-C levels in the blood and a lower risk for major cardiovascular events. ION449 is a LIgand Conjugated Antisense (LICA) medicine being developed by AstraZeneca as part of a collaboration between Ionis and AstraZeneca.

The Phase 2b, randomized, double-blind, placebo-controlled trial will enroll approximately 108 participants, aged 18-75, who have LDL-C levels between 70 and 190 mg/dL and are receiving moderate- or high-intensity statin therapy as defined by the American College of Cardiology/American Heart Association (ACC/AHA) guidelines on blood cholesterol management. The primary objective is to assess the effect of different doses of ION449 on LDL-C compared to placebo at Week 12 in patients taking baseline statin therapy.  The study will evaluate three dose levels of ION449 versus placebo, all administered once a month by subcutaneous injection. Safety and tolerability will be evaluated along with a number of secondary endpoints. Learn more about the trial at: https://clinicaltrials.gov/ct2/show/NCT04641299. 

In a Phase 1 study reported at the American Heart Association (AHA) Scientific Sessions on November 13, single subcutaneous doses of ION449 (AZD8233) demonstrated dose-dependent mean reductions in circulating plasma PCSK9 and LDL-C levels of >90 percent and up to 70 percent, respectively, in subjects who had a baseline LDL-C between 100 and 190 mg/dL without concomitant statin therapy. Doses up to 120 mg were evaluated. ION449 was observed to be safe and well-tolerated at all dose levels. 

“Results from the Phase 1 study showed that ION449 potently reduces PCSK9 and LDL cholesterol. ION449 demonstrated best-in-class potential for PCSK9 inhibition and LDL-C reduction, supporting larger clinical trials that are now underway to further evaluate efficacy and safety,” said Sotirios “Sam” Tsimikas, M.D., senior vice president, clinical development and cardiovascular franchise leader at Ionis. “The growing evidence supporting Ionis’ advanced LICA technology in cardiovascular disease holds promise for more effective approaches to lower LDL-C and to address cardiovascular disease, the leading cause of death worldwide.”

Dr. Tsimikas will provide an update on Ionis’ cardiovascular programs during Ionis’ Virtual Investor Day, Dec. 7, 2020, beginning at 12 p.m. EST.

Ionis earned a milestone payment of $20 million from AstraZeneca for the Phase 2b clinical trial initiation of ION449. Ionis and AstraZeneca are collaborating on potential treatments for kidney disease, cardiometabolic disease and cancer.

About Ionis Pharmaceuticals, Inc.

As the leader in RNA-targeted drug discovery and development, Ionis has created an efficient, broadly applicable, drug discovery platform called antisense technology that can treat diseases where no other therapeutic approaches have proven effective. Our

Read More
medicine

ZYUS Life Sciences Strengthens Leadership in Evidence-Based Medicine with Appointment of Clinical Advisory Committee

SASKATOON, Saskatchewan–(BUSINESS WIRE)–ZYUS Life Sciences Inc. (“ZYUS”), a Canadian life sciences company leading scientific research and development in phyto-therapeutics, is pleased to announce the formation of a Clinical Advisory Committee to provide strategic advice and guidance on ZYUS’ clinical trial programs. Five committee members have been appointed to the Clinical Advisory Committee, adding additional medical, scientific, and clinical expertise to its experienced leadership team. This announcement is an important step in ZYUS’ integrated clinical development program and supports the company’s ambitions to pioneer the next generation of life sciences through an evidence-based approach.

Chaired by ZYUS’ Chief Medical Officer, Dr. Lionel Marks de Chabris, a leading expert in chronic pain management and addictions medicine, the ZYUS Clinical Advisory Committee includes four initial committee members including Dr. Mary Lynch, Dr. David J. Shulkin, Dr. Cedric Francois and Dr. Alice Zwerling. As ZYUS scales its clinical trial programs, the Clinical Advisory Committee will work closely with the research team to provide input and guidance on clinical development strategies and evaluate the clinical trial progress.

Each of the named Clinical Advisory Committee members bring remarkable medical leadership and expertise to their advisory roles. Dr. Mary Lynch ranks among North America’s leading experts in pain management. She is a Professor in the Departments of Anesthesiology, Pain Management and Perioperative Medicine, Psychiatry and Pharmacology in the Faculty of Medicine at Dalhousie University. In addition to being the founding director of the Canadian Consortium for the Investigation of Cannabinoids, Dr. Lynch co-chairs the Canadian Pain Strategy and is a member of the Royal College of Physicians and Surgeons Working Group on Pain Management. Her expertise in pain management is directly aligned with ZYUS’ research into the potential of phyto-therapeutics to manage chronic and neuropathic pain, and Dr. Lynch’s scientific research and thought-leadership in this space will provide valuable guidance to ZYUS’ clinical approach.

Providing cross-border expertise and widely respected medical leadership, Dr. David J. Shulkin will bring his decades of experience leading some of North America’s largest and most sophisticated medical networks to the ZYUS Clinical Advisory Committee. Dr. Shulkin previously served as the ninth Secretary of the US Department of Veterans Affairs and prior to holding that role, was appointed Under Secretary for Health by President Obama and confirmed unanimously by the U.S. Senate. In his role as Secretary of the U.S. Department of Veterans Affairs, he represented 21 million American veterans and was responsible for the country’s largest integrated health care system with over 1,200 sites of care. In addition to his roles in the public sector, Dr. Shulkin has served as the chief executive of multiple hospitals and health systems, and has been named as one of the “One Hundred Most Influential People in American Healthcare” by Modern Healthcare. Dr. Shulkin’s experience as a physician, hospital CEO and Secretary of the Department of Veterans Affairs provides unique insights into the medical, societal and political implications of ZYUS’ clinical trial programs.

The co-founder and Chief Executive Officer and President of Apellis Pharmaceuticals,

Read More
medicine

Baylor Scott & White Health announces new affiliations with Baylor College of Medicine and Texas A&M University to further expand the pipeline of exceptional clinical talent for Texas

Baylor Scott & White Health, the largest not-for-profit health system in the state of Texas, today announced two separate academic affiliations: a new affiliation with Baylor College of Medicine and an expanded affiliation with its long-time partner Texas A&M University. Both alliances are aimed at training future clinicians and developing programs that advance high-quality care and healthcare innovation. 

“We believe these long-term partnerships will ensure that our patients will have access to breakthrough medical discoveries and cutting-edge treatments from world-class physicians for generations to come,” said Peter J. McCanna, president, Baylor Scott & White.  

Baylor Scott & White offers the full continuum of care, from primary to award-winning specialty care, through an integrated care delivery network of 52 hospitals and more than 1,100 access points including flagship academic medical centers in Dallas and Temple. Baylor Scott & White extends investigational expertise across more than 50 medical specialties through Baylor Scott & White Research Institute, which provides the business and regulatory infrastructure to accelerate medical breakthroughs and innovative new treatment models. Baylor Scott & White Research Institute oversees nearly 2,000 active trials each year. 

Establishing a new Baylor College of Medicine regional medical school campus in Temple 

Baylor Scott & White and Baylor College of Medicine today announce a new affiliation to enhance the organizations’ collective impact on the statewide effort to train more students to become physicians.  

Additionally, the affiliation will allow for opportunities for expanded research and program development, with the ultimate goal of improving health and healthcare for Texans. 

The new 20-year relationship will be anchored by the development of a progressive four-year regional medical school campus in Temple, Texas, where Baylor College of Medicine will offer a curriculum highlighted by an approach that fully integrates health system and university resources to deliver adaptive and personalized medical education.  

“This is a great opportunity to expand Baylor College of Medicine’s outstanding medical education programs to a regional medical school campus,” said Dr. Paul Klotman, president, CEO and executive dean of Baylor College of Medicine. “We are looking forward to being in Temple.”  

Through a holistic recruiting process, Baylor College of Medicine focuses on recruiting a diverse class of students who are from and reflective of the communities that Baylor Scott & White serves. An inaugural class of 40 medical students is anticipated to begin training in Fall 2023. The campus will increase by 40 students a year over four years. The medical school is excited to welcome 160 more students to experience the caliber of education offered by Baylor College of Medicine. 

Baylor College of Medicine will strive to maintain a high percentage of Texas residents in the medical school. The goal of the new affiliation is to further expand the physician workforce pipeline for Texas with graduates having the opportunity to serve as future leaders in communities and providing outstanding clinical care for the people of Texas.  

The regional medical school campus in Temple will be overseen by the Baylor College of Medicine School of Medicine Dean, and

Read More
medicine

Rocket Pharmaceuticals Receives Funding from the California Institute for Regenerative Medicine for Phase 1 Clinical Trial of RP-L401 for Infantile Malignant Osteopetrosis

NEW YORK–(BUSINESS WIRE)–Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that the California Institute for Regenerative Medicine (CIRM) has awarded Rocket a $3.7 million CLIN2 grant award to support the clinical development of its lentiviral vector (LVV)-based gene therapy, RP-L401, for the treatment of Infantile Malignant Osteopetrosis (IMO), a rare, severe monogenic bone resorption disorder characterized by skeletal deformities, neurologic abnormalities and bone marrow failure. The CIRM was founded in 2004 following the passing of Proposition 71 or the California Stem Cell Research and Cures Initiative, which allowed $3 billion in state funding for stem cell research conducted in California. This will be Rocket’s second CIRM grant after receiving one in 2019 for the development of the company’s gene therapy for Leukocyte Adhesion Deficiency-I (LAD-I).

“We’re grateful the CIRM has recognized the promise of RP-L401 for IMO, a devastating pediatric rare disease for which the primary treatment option is allogeneic bone marrow transplant,” said Jonathan Schwartz, M.D. Chief Medical Officer and Senior Vice President of Rocket. “RP-L401 could be a potentially curative treatment for this devastating disorder that affects children at a young age, and we are thankful to have this meaningful support from the CIRM to move our program forward for these families.”

Rocket’s Investigational New Drug Application (IND) for RP-L401 was accepted by the U.S. Food and Drug Administration (FDA) in June of 2020, and the gene therapy received Fast Track designation from the FDA in August 2020. Proceeds from the grant will help fund clinical trial costs, as well as provide manufactured drug product for Phase 1 patients enrolled at the U.S. clinical trial site, University of California, Los Angeles, led by principal investigator Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics, Pediatrics (Hematology/Oncology), Molecular and Medical Pharmacology, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California, Los Angeles. The non-randomized, open-label Phase 1 clinical trial will enroll two pediatric patients, one month of age or older. The trial is designed to assess safety and tolerability of RP-L401, as well as preliminary efficacy, including potential improvements in bone abnormalities/density, hematologic status and endocrine abnormalities. Further information about the clinical program is available here.

About Infantile Malignant Osteopetrosis

Infantile Malignant Osteopetrosis (IMO) is a rare, severe autosomal recessive disorder caused by mutations in the TCIRG1 gene, which is critical for the process of bone resorption. Mutations in TCIRG1 interfere with the function of osteoclasts, cells which are essential for normal bone remodeling and growth, leading to skeletal malformations, including fractures and cranial deformities which cause neurologic abnormalities including vision and hearing loss. Patients often have endocrine abnormalities and progressive, frequently fatal bone marrow failure. As a result, death is common within the first decade of life. IMO has an estimated incidence of 1 in 200,000. The only treatment option currently available for IMO is an

Read More
medicine

The Lancet Respiratory Medicine: Clinical trial finds inhaled immune response protein increases odds of recovery for hospitalised COVID-19 patients

Peer-reviewed / Randomised Controlled Trial / People

  • Inhaled delivery of a formulation of a key protein involved in the immune response – interferon beta-1a – to hospitalised COVID-19 patients in the UK reduced the odds that they would develop severe disease or die from SARS CoV-2 infection.
  • Those patients who received inhaled interferon beta-1a were more than twice as likely to recover from COVID-19 infection to a point where everyday activities were not limited compared with those who received a placebo.
  • The trial included 101 patients, with the data providing strong rationale for larger studies to further investigate the impact of this treatment on clinical outcomes.

Hospitalised COVID-19 patients in the UK who received an inhaled form of interferon beta-1a (SNG001) were more likely to recover and less likely to develop severe symptoms than patients who received a placebo, according to a new clinical trial published in The Lancet Respiratory Medicine journal. This is the first evidence published in a peer-reviewed medical journal that inhaled interferon beta-1a could lessen the clinical consequences of COVID-19 and serves as proof-of-concept that this treatment could help hospitalised patients recover, but further research is required.

As the number of COVID-19 infections continues to rise around the world, there is a pressing need to develop new treatments for the more severe and life-threatening symptoms such as pneumonia and respiratory failure.

Interferon beta is a naturally occurring protein that coordinates the body’s immune response to viral infections. Laboratory studies have found that the SARS CoV-2 virus directly suppresses the release of interferon beta, while clinical trials demonstrate decreased activity of this important protein in COVID-19 patients. The formulation of interferon beta used in this new study – SNG001 – is directly delivered to the lungs via inhalation and has been trialled in the treatment of asthma and chronic obstructive pulmonary disease (COPD). This study aimed to evaluate the safety and efficacy of SNG001 to treat hospitalised COVID-19 patients.

The trial was conducted at nine UK hospitals with patients who had a confirmed SARS-CoV-2 infection. It compared the effects of SNG001 and placebo given to patients once daily for up to 14 days, and followed up patients for a maximum of 28 days after starting the treatment. Patients were recruited from March 30 to May 30, 2020, and were randomly assigned to receive the treatment or a placebo. All members of the research team were blinded to which group the patients were allocated. During the study, changes in the clinical condition of patients were monitored.

Of the 101 patients enrolled in the study, 98 patients were given the treatment in the trial (three patients withdrew from the trial) – 48 received SNG001 and 50 received a placebo. At the outset of the trial 66 (67%) patients required oxygen supplementation at baseline (29 people in the placebo group and 37 in the SNG001 group). Patients who received SNG001 were twice as likely to show an improvement in their clinical condition at day 15 or 16, compared with

Read More
medicine

Greenwich LifeSciences, Inc. Announces Partnership with Baylor College of Medicine for its Planned Phase III Clinical Trial

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the formation of a partnership with Baylor College of Medicine in Houston, Texas to act as the lead clinical site for the Company’s upcoming Phase III clinical trial. Professor Mothaffar F. Rimawi has agreed to serve as the Global Principal Investigator of the Phase III clinical trial, and Professor C. Kent Osborne and Professor Rimawi are expected to serve as the first members of the Company’s Clinical Advisory Board for the development of GP2 immunotherapy across all indications and HER2 expressing cancers.

Snehal Patel, CEO of Greenwich LifeSciences, commented, “We are pleased to have entered into this collaboration with such prominent key opinion leaders who are truly committed to evaluating the potential of GP2 immunotherapy. Due to GP2’s safety profile, GP2 immunotherapy may provide clinicians with an option to deescalate treatment of patients by reducing the use of other, more toxic and expensive standard of care treatments. Both Professors Rimawi and Osborne have already introduced us to other breast cancer clinical sites and clinical leaders who have provided input into the design of the upcoming Phase III trial and who have expressed an interest in participating in the Phase III trial as high enrollment sites. In addition, we have also been jointly exploring the addition of both US and European breast cancer cooperative groups to more rapidly expand the clinical team.”

Professor Rimawi added, “We are excited to jointly evaluate the potential of GP2 immunotherapy. We believe that our patients will seek to participate in the upcoming trial as the GP2 Phase IIb clinical trial data suggests that GP2 could be both safe and effective and could be easily administered during standard of care follow-up visits. Our patients are seeking safe preventative treatments that allow them to transition away from the trauma of surgery, trastuzumab-based therapies, other HER2 targeted therapies, chemotherapy, and radiation as they seek to return to normal and healthy lives.”

Professor Osborne commented, “Bringing new alternatives to chemotherapy and improving quality of life for patients undergoing treatment for breast cancer are primary focuses of the Breast Cancer Program. GP2 immunotherapy may represent one such opportunity, and we look forward to collaborating with Greenwich LifeSciences and supporting the planned clinical trial with the resources of both the Dan L Duncan Comprehensive Cancer Center and the Baylor College of Medicine.”

Professor Mothaffar F. Rimawi is board certified in internal medicine, hematology and medical oncology, and serves as both Executive Medical Director and Co-Leader of the Breast Cancer Program at the Dan L Duncan Comprehensive Cancer Center.

Professor C. Kent Osborne is board certified in internal medicine, hematology and medical oncology, and serves as both the Tina and Dudley Sharp Chair in Oncology and the founding Director of the Dan L Duncan Comprehensive Cancer Center. Professor Osborne is also Professor of Medicine and Molecular and

Read More
health

TLC Announces Acceptance of Manuscript on Anti-COVID-19 Program by Clinical and Translational Science Journal

Technology can be quickly translated and applied to other drugs for direct, extended release delivery to the lungs and is open for collaboration

SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Nov. 03, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, today announced that the manuscript describing how inhalable liposomal hydroxychloroquine (TLC19) may provide clinical benefit and serve as a potential treatment for COVID-19 has been peer-reviewed and accepted by Clinical and Translational Science (CTS) journal. CTS highlights original research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease and is an official journal of the American Society of Clinical Pharmacology and Therapeutics (ASCPT).

“We are honored to be sharing this peer-reviewed manuscript in an internationally acclaimed journal,” said George Yeh, President of TLC. “CTS has a collection of clinical pharmacology research from various potential treatments such as remdesivir, favipiravir, and lopinavir/ritonavir. Acknowledgment of our work by CTS further fortifies the soundness of our strategy of preferential delivery to the lungs. In these unprecedented times, we wish to do all that we can to help, and we openly welcome partnerships to re-formulate drugs with high potency against SARS-CoV-2 virus but low bioavailability utilizing our proprietary inhalable liposomal formulation in order to create more potential remedies to address this global pandemic.”

The accepted manuscript titled “A Strategy to Treat COVID-19 Disease with Targeted Delivery of Inhalable Liposomal Hydroxychloroquine: A Pre-clinical Pharmacokinetic Study” can be found on the ASCPT website using the following link: https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1111/cts.12923. The research, which was previously available as pre-print on bioRxiv.org, is a collaborative work by TLC in conjunction with key opinion leader in respiratory therapies – Dr. Huey-Dong Wu, Senior Pulmonologist at the Department of Integrated Diagnostics and Therapeutics at National Taiwan University Hospital – and the leading authority in infectious diseases – Dr. Yee-Chun Chen, Professor of Medicine at National Taiwan University Hospital and College of Medicine, Investigator of the National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes of Taiwan, and Board Member and Vice President of the International Society for Human and Animal Mycology (ISHAM).

“There is an unmet medical need for a therapy that is accessible and affordable for everyone affected by the COVID-19 pandemic,” said Dr. Chen. “Altering the route of administration of hydroxychloroquine from oral to inhalation substantially increases exposure in the airways and lungs while decreasing exposure in the system, and a liposomal formulation allows sustained residence of the drug in the lungs. I am happy to see these principles reflected in the results of this preclinical study and look forward to seeing more encouraging data from the clinical trials.”

A Phase I randomized, vehicle-controlled, blinded study evaluating the safety, tolerability, and pharmacokinetics of inhaled TLC19 in healthy volunteers is ongoing.

About TLC19
TLC19 is a liposomal suspension of hydroxychloroquine (HCQ) for inhalation. HCQ has shown potential in prophylaxis and/or treatment for COVID-19 in in vitro and

Read More
health

Global Oncolytic Virus Therapy Market 2026 Companies Clinical Trials Insight

Oncolytic Virus Immunotherapy Market Offers US$ 700 Million Opportunity With More Than 125 therapies in Clinical Trials says Kuick Research

DELHI, India, Nov. 02, 2020 (GLOBE NEWSWIRE) — “Global Oncolytic Virus Immunotherapy Market, Dosage, Price & Clinical Trials Outlook 2026” Report Highlights:

  • Global Oncolytic Virus Immunotherapy Market: US$ 700 Million Opportunity

  • Global Oncolytic Virus Immunotherapy Clinical Trials: >125 Therapies In Trials

  • USA Dominates Oncolytic Virus Immunotherapy Clinical Trials: >50 Therapies In Trials

  • Comprehensive Insight on Clinical & Non Clinical Issues Related to Global Oncolytic Virus Immunotherapy Market Development

  • Approved Oncolytic Virus Immunotherapy: 2

  • Global Research Progress & Medical Advancement Insight

  • Imlygic (Talimogene laherparepvec) & Oncorine: Dosage, Price & Patent insight

Download Report: https://www.kuickresearch.com/report-oncolytic-virus-immunotherapy-market-size-sales-clinical-trials-cancer-oncology-melanoma-report-talimogene-laherparepvec-imlygic–oncorine

Recent breakthrough with respect to oncolytic virus therapy in the oncology pharmaceutical industry has set up remarkable achievements in terms of understanding all the important proposed hallmarks for counteracting cancer mechanism of action. The important clinical management terms related with oncolytic virus therapy is believed to be extracting and abolishing all the disadvantages and limitations that were associated with all the commercially available cancer therapies. Certain challenges that were residing in the oncology pharmaceutical industry is estimated to end once the market associated with oncolytic virus therapy comes into full power in terms of financial and commercial availability.

The wide range applications of oncolytic virus therapy with respect to different types of cancers such as melanoma, prostate cancer, breast cancer, ovarian cancer and many others is estimated to deliver a very bulk amount of research and development investment for the future progress of the therapy at global level. The estimated future market competition oncolytic virus therapy is intense as the market is associated with some of the leading drug research and development players, high research marketing as well as a monopoly situation in treating different types of cancers. As per the study conducted for the market, it is estimated that in the next few years, the market will surpass USD 700 Million by 2026.

In a short period of time, oncolytic virus therapy has selectively replaced all the other traditional cancer therapies available for the cancer patients as the therapy is adjoined with large number of innovative principles. Several therapeutic agents under oncolytic virus therapy has entered clinical studies and have specifically proven to be safe and efficient for human use. Although the market is few years old but the related research and development sector as well as future research is believed to make the system functional as well as effective for millions of cancer patients who have been suffering very badly from past few years.

With the arrival of oncolytic virus therapy for the cancer patients, all the barriers that were pursed in the oncology pharmaceutical industry have been overcome promisingly as the therapy has entered and been recognized as a mainstream treatment facility for the clinical management of the cancer cells. The long-term future of the market at global level appears to be developing at a rate that is highly advanced as researchers

Read More